AstronauTx has ppointed Michelle Mellion (pictured) as Chief Medical Officer (CMO) and Deb Gouveia as Vice President, Clinical Operations and Development Strategy.
AstronauTx is a biotechnology company developing therapeutics to treat Alzheimer’s Disease and other neurological disorders by improving sleep architecture.
Mellion is a seasoned neurologist and clinical development leader, bringing more than two decades of experience across academia and the biotechnology industry. She has a strong track record of advancing innovative therapies for neurological and rare diseases, including neuromuscular disorders.
Most recently, Mellion was CMO at PepGen and EveryONE Medicines, where she led clinical development efforts for oligonucleotide therapeutics and individualised medicines for ultra-rare conditions. Earlier in her career, she held positions at Biogen, Vertex Pharmaceuticals and Fulcrum Therapeutics, contributing to programmes spanning remyelination, pain and facioscapulohumeral muscular dystrophy (FSHD).
In her role as CMO at AstronauTx, Mellion will lead the clinical strategy and development activities, working closely with the executive and leadership teams to advance its pipeline into the clinic.
Gouveia brings more than 25 years of experience building and leading clinical operations, regulatory, quality and development infrastructure across emerging biotechnology companies.
Jane Rhodes, Chief Executive Officer at AstronauTx commented: “Michelle’s track record in advancing therapies for neurological and rare diseases aligns strongly with our ambition to develop transformative treatments targeting sleep architecture. As we build out our clinical capabilities and progress our pipeline, the appointments of Michelle and Deb strengthen the expertise driving our transition into clinical-stage development.”
Dr. Michelle Mellion, Chief Medical Officer at AstronauTx added: “AstronauTx represents a rare opportunity to help define an entirely new therapeutic category at the intersection of sleep biology and neurodegenerative disease. The Company’s innovative approach to leveraging slow-wave sleep modulation as a potential disease-modifying strategy is both scientifically compelling and strategically differentiated, and I am excited to work with the team to advance these programmes into clinical development.”